ARGX (argenx SE) Operating Cash Flow per Share : $0.00 (TTM As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is argenx SE Operating Cash Flow per Share?

argenx SE's operating cash flow per share for the three months ended in Mar. 2025 was $0.00. argenx SE's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 51.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for argenx SE's Operating Cash Flow per Share or its related term are showing as below:

ARGX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -86.5 Med: -22.3 Max: 84.7
Current: 51.3

During the past 13 years, argenx SE's highest 3-Year average Operating Cash Flow per Share Growth Rate was 84.70% per year. The lowest was -86.50% per year. And the median was -22.30% per year.

ARGX's 3-Year OCF Growth Rate is ranked better than
88.17% of 1217 companies
in the Biotechnology industry
Industry Median: 9.1 vs ARGX: 51.30

argenx SE Operating Cash Flow per Share Historical Data

The historical data trend for argenx SE's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Operating Cash Flow per Share Chart

argenx SE Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-8.78

-11.88

-15.87

-7.35

-1.27

argenx SE Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of argenx SE's Operating Cash Flow per Share

For the Biotechnology subindustry, argenx SE's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

argenx SE's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where argenx SE's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

argenx SE Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

argenx SE's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-82.747	/	65.178
	=	-1.27

argenx SE's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	0	/	65.664
	=	0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

argenx SE Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of argenx SE's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

ARGNF:USA ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.